Share Name Share Symbol Market Type Share ISIN Share Description
Tekcapital LSE:TEK London Ordinary Share GB00BKXGY798 ORD £0.004
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 30.00p 28.00p 32.00p 30.00p 30.00p 30.00p 10,000 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 0.6 -2.0 -5.0 - 12.80

Tekcapital Share Discussion Threads

Showing 401 to 424 of 425 messages
Chat Pages: 17  16  15  14  13  12  11  10  9  8  7  6  Older
DateSubjectAuthorDiscuss
10/10/2017
14:38
And the award for the most tenuous link with TEK on any post ever goes to boom boom spam spam boom boom spam spam post 421 of 421 filtered
mach100
10/10/2017
12:39
bzm is rolling
boom boom bang bang
10/10/2017
11:50
Yes. Rise has held up too due to lack of sellers. The two large buys today were enough to drive this up. I suspect it is not a leak but just exaggerated movement caused by large buys in thin trading.
mach100
10/10/2017
09:04
Looks like there's been a leak of some kind. Someone appears to be in the know. Inevitably I no longer hold. Good luck with it.
speedsgh
10/10/2017
08:59
Really pleased to see these rise, hopefully there's something significant behind it 🤞
battlebus2
31/7/2017
06:26
Fairly upbeat Interims this morning, some changes to accounting practices with fair etc but no major IP deals as yet.
battlebus2
31/5/2017
21:27
Good summary PJ1, I still get excited when I see an RNS BY TEK as I think this one is going to be the breakthrough. Only to find they have accumulated some tech which they look forward to bringing to commercialisation and will update the market in due course. It will be worth holding at least 1 share in TEK for that feeling alone. For everything else of course there is Mastercard.
mach100
31/5/2017
14:30
I'm possibly being harsh on cash burn, it seems the £2.1 raised in May 2015 lasted them over 18 months, so say £1.5m a year? (excluding fees)
pj 1
31/5/2017
14:23
Its as good as 12 months since they acquired the licences of Slyde, Passport and SNAP. No news other than placings to sell them via Belluscura. What have those sales persons been doing for 12 months-ish then? They had $1.8m at Nov year end plus raising a guess net $2.2m = $4m. x2 'acquisitions' say $2/3m plus cash burn. Its not hard to see where its going. Any licence fees from Cackle are probably years away, unless they sell the patent, or a manufacturer is prepared to pay up front? doubtful. Advances in battery technology probably eliminates the mobile battery charger, so its all eyes on salt reduction? imo. What happened to the 18 month target for commercialisation of any project given in late 2015 was it via Proactive Investors? IMO I think its now best to look at this as a pure numbers game, the more they sign up the greater the chance of 'striking oil'. Que RNS tomorrow LOL
pj 1
31/5/2017
12:25
Not sure PJ. I would have gone, He did one before at Mayfair and it went down well. This one might take place later I suppose so I can give you numbers then. The downside is that they have garnered lots of tech since the last presentation but have monetised hardly any. The selling point of the last presentation I saw was that is could find patents quickly and was signing up user. The strategy seems way different now,
mach100
31/5/2017
08:28
Mach100. Any idea of how much interest was expressed in the Investor evening?
pj 1
31/5/2017
08:13
They cancelled the investor evening late Friday that was scheduled for tomorrow. Looks like the CEO was working on today's deal. Maybe he pulled it off ahead of schedule as surely it would have given extra currency to the presenattion.
mach100
09/5/2017
21:16
I'm unsure if I have posted this before or not.... Cackle Bake will (if progressed) have to go through lots of regulatory approval which could take years imo The reduced Salt much less so, so I'd perhaps be inclined to 'home' in on that one more than Cackle.... The main problem being with University technology is that we, as investors, rarely know what else is out there that could be better (or worse), or what the competition are doing, or more easily accepted by the relevant Industry....No-one remembers the runners up do they? More worrying for me is that TEK seem more concerned will promoting Belluscura than anything else, with an unknown funding requirement. I also do not like the unannounced strategy change, why not be more open? Then again as BB2 says, high returns if anything gets a signature on the bottom.....
pj 1
09/5/2017
20:06
Looks like progress is being made in a number of our technologies but we really need a license deal that will keep us funded otherwise it maybe the floating of Belluscura that will do that. Potential is still enormous imv so will continue to hold.
battlebus2
09/5/2017
20:05
After hours RNS is slack. "We believe that there is a significant value to be realised from the patent rights that we have acquired to-date, and we are strategically moving forward with our commercialisation efforts, including seeking to out-license our patents and IP. Negotiations are on-going with uSalt(tm), Crackle-baked(tm) and our head-mounted display/optics patents portfolio and we will update the market in due course as specific properties are out licensed". Some repeated promises that we've heard before. Will they deliver? I've no idea!
rp19
09/5/2017
19:07
Now that's a different matter 🍺
battlebus2
09/5/2017
19:01
Don't like after hours... unless it's a lock-in of course ;-)
speedsgh
09/5/2017
18:59
Haven't seen them yet. Don't like after hours!!!
battlebus2
09/5/2017
18:57
By all accounts production of Jam For Tomorrow is going great guns! "the Board is confident that continued investment in growth remains the right policy". "Out-license negotiations in respect of µSalt™, Crackle-baked® and Tekcapital's portfolio of optics patents remain ongoing"
speedsgh
09/5/2017
18:32
17;15 and Results announced. Hardly ideal at 'no one is watching o'clock'. Confirmed by the silence on the thread. I'm not sure what to make of them on a first read. obviously all eyes turn to the Cash.......?
pj 1
03/3/2017
10:11
4 announcements in one week! Let's hope all these product launches lead to increased revenues & profits in due course so that the company doesn't have to continue relying on tapping the markets to fund itself. "Monsieur Gross. With zeese announcements, you are really spoiling us" [said in best Ferrer Rocher accent] - HTTPS://youtu.be/hMlP_Moo0bE
speedsgh
03/3/2017
07:45
RNS RNS Number : 4031Y Tekcapital plc 03 March 2017  3 March 2017 Tekcapital plc ("Tekcapital" or the "Company") BELLUSCURA LTD LAUNCHES PASSPORT® DISPOSABLE TROCAR IN USA Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has launched Passport® in the United States. Passport is a disposable trocar used in laparoscopic, or 'keyhole' surgery, and features the patented SmartTip™ technology, designed to be compatible with the Da Vinci®1 S and Si robotic surgical systems. Passport, with its unique seal, is used as the access point for the endoscope camera which allows the surgeon to visualise the procedure site. The SmartTip controls the cutting blade to prevent accidental deployment inside the patient and potential tissue damage. It is estimated that more than 7.5 million laparoscopic procedures are performed annually2, with 2.8 million being performed in the US alone. Laparoscopic procedures continue to replace more invasive surgery because of the faster recovery, lower surgical headcount requirement and better training.3 Please click here for picture of Passport® http://www.rns-pdf.londonstockexchange.com/rns/4031Y_-2017-3-2.pdf Bob Rauker, Belluscura's CEO said: "The launch of this Passport trocar provides Belluscura with a presence in the surgical device field. Passport is the first of a family of trocars and cannulae that Belluscura will seek to launch over the coming years. Together, these will form a range of products to support surgeons in an array of specialties." About Belluscura: Belluscura Limited is a global medical device company founded in Oxford, England. Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines. Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com. Tekcapital owns approximately 65% of the share capital of Belluscura.
dynam1te
02/3/2017
07:55
Belluscura Ltd Launches Slyde in EU RNS RNS Number : 2739Y Tekcapital plc 02 March 2017 2 March 2017 Tekcapital plc ("Tekcapital" or the "Company") BELLUSCURA LTD LAUNCHES SLYDE™ IN EU Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has launched its Slyde product in the European Union. Slyde is a light and compact sled for moving its occupant safely down stairs or over rough ground in the event of an emergency evacuation. It provides a safe and efficient way to evacuate non-ambulatory individuals from any multi-storey building using the stairways. Slyde folds up and stores in stacks of up to five units in a storage sleeve. The sleeve can be wall-mounted for quick access in key locations. Slyde is sold in two sizes with a range of accessories designed to safely lower people in the event of an emergency evacuation. Stephen Appelbee, Belluscura's International Director of Global Sales said: "We are delighted to make this important step towards becoming a truly international medical device company. Our first product, Slyde, is a good example of Belluscura's mission to provide premium medical device products at affordable prices, and we expect it to be widely adopted by hospitals, schools, hotels and rescue services. We intend to use the expertise of local distributors in each region, starting in the European Union." Slyde is already available and selling in the USA. About Belluscura: Belluscura Limited is a global medical device company founded in Oxford, England. Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines. Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com. Tekcapital owns approximately 65% of the share capital of Belluscura.
dynam1te
01/3/2017
08:06
Belluscura Ltd Launches Wire CaddyT In USA RNS RNS Number : 1208Y Tekcapital plc 01 March 2017 1 March 2017 Tekcapital plc ("Tekcapital" or the "Company") BELLUSCURA LTD LAUNCHES WIRE CADDY™ IN USA Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has launched its Wire Caddy™ product in the United States. The Wire Caddy™ is an innovative wire management system that provides lubrication and organization during multi-wire, multi-exchange operating room cases, such as cardiology interventions, uterine fibroid embolizations and tibial angioplasties. The Wire Caddy™ was designed by interventional radiologist Dr Shaun Samuels to address unique challenges in complex surgical procedures, especially those involving multi-wire and multi-exchange cases. Its unobtrusive positioning allows quick access to lubricated guidewires during surgical procedures in interventional radiology, catheterization laboratory, vascular suite and other operating room operations. Belluscura's Wire Caddy™ is particularly useful for single operators, interventional radiology trainees, fellows and residents. Belluscura's Chief Executive Officer Bob Rauker said: "Wire Caddy™ is an excellent component in our product portfolio, which offers premium and affordable solutions to meet the needs of the patient and healthcare providers". About Belluscura: Belluscura Limited is a global medical device company founded in Oxford, England. Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines. Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com. Tekcapital owns approximately 65% of the share capital of Belluscura. For further information, please contact: Tekcapital Plc Clifford M. Gross, Ph.D. info@tekcapital.com Allenby Capital Limited (Nominated Adviser & Joint Broker) +44 (0) 20 3328 5656 Jeremy Porter / Alex Brearley Dowgate Capital Stockbrokers (Joint Broker) +44 (0) 1293 517744 David Poutney / James Serjeant Walbrook PR Ltd +44 (0) 20 7933 8780 Paul Cornelius / Helen Cresswell / Sam Allen tekcapital@walbrookpr.com Tekcapital plc - The World's Largest University Network for Open Innovation Tekcapital helps clients profit from new, university-developed intellectual properties. With its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com LEI: 213800GOJTOV19FIFZ85
dynam1te
Chat Pages: 17  16  15  14  13  12  11  10  9  8  7  6  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20171118 23:44:21